Pfizer CentreOne launches Enviero green-chemistry progesterone API16 Apr 2018
Carbon footprint reduced by more than 70%.
Pfizer CentreOne has introduces Enviero progesterone into the API marketplace. Enviero progesterone is produced by a first-of-its-kind progesterone synthesis developed by Pfizer that reduces waste, greenhouse gas emissions and use of hazardous solvents. Results include cutting the carbon footprint of the progesterone manufacturing process by more than 70% and eliminating the use of metal catalysts. Pfizer CentreOne is a global contract manufacturing organization embedded within Pfizer Inc. and a leading supplier of steroid and hormone APIs and intermediates.
"Enviero green-chemistry progesterone represents a step change in progesterone API synthesis,” said Greg Scanlon, API business lead for Pfizer CentreOne. “And it’s in keeping with Pfizer’s commitment to reduce its impact on the environment.” Developed over 12 years, Enviero progesterone is manufactured via a proprietary biocatalytic process based on plant sterols. Scanlon continued: “We are pleased to offer Enviero progesterone to customers looking for a reliable supply of high-quality progesterone for their medicines."
While new to Pfizer CentreOne customers, Enviero progesterone has been used by Pfizer as an intermediate in the manufacture of its own medications for the past 4 years. More than 500 metric tons have been manufactured to date for internal use.
The compound is manufactured exclusively in the US at Pfizer’s Kalamazoo, Michigan, facility. As with all Pfizer CentreOne APIs, all processing steps for Enviero progesterone are performed under Pfizer’s stringent quality management system, and the compound is backed by technical and regulatory support for the life of the product.
Enviero progesterone is the first API to be launched from Pfizer CentreOne’s green-chemistry program. According to the US Environmental Protection Agency, “Green chemistry is the design of chemical products and processes that reduce or eliminate the use or generation of hazardous substances.” Green chemistry is applied at the process level – in this case, API synthesis – to minimize waste and pollution upfront.
Spanish CDMO working ahead of EU serialisation deadline
6 Dec 2018
Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.Read more
Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases
5 Dec 2018
The financing will power the global commercial launch of the company's Fluidity One system.Read more
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD
4 Dec 2018
The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.Read more
India to have strongest global growth in 2019?
4 Dec 2018
Main drivers cited as ‘high-growth domestic market’ and ‘expanding manufacturing exports’.Read more
Catalent to expand biologics packaging capabilities
3 Dec 2018
Company's $14 million investment follows twentieth commercial drug approval at Bloomington, Indiana site.Read more
Merck successfully divests Consumer Health
2 Dec 2018
Closing of sale to Procter & Gamble at a cash purchase price of €3.4 billion completed.Read more
Digital manufacturing is a top priority for life sciences
29 Nov 2018
Zenith Technology survey reveals that more than half of those surveyed believe that Industry 4.0 will drive the most change.Read more
NIH to evaluate effectiveness of male contraceptive skin gel
28 Nov 2018
The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.Read more
QPS expands US-based Phase I clinical trial capabilities
27 Nov 2018
Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.Read more
Hikma announces injectable licensing agreement
27 Nov 2018
Company provided with exclusive rights to market a suite of Hansoh's injectable oncology medicines within the US for the next 5 years.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation